Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.52 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.52 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.52 |
| ▸ | CYP2A7 | P20853 | 2/20 | 0.52 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.52 |
| ▸ | CYP2F1 | P24903 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2045217 | 0.84 | ALDH1A1 (0.67) | ALDH1A1KDM4ERAB9ASMN1; SMN2HPGD | |
| SCHEMBL3685934 | 0.83 | TAAR1 (0.55) | ALDH1A1KDM4ERAB9ASMN1; SMN2HPGD | |
| SCHEMBL22779406 | 0.83 | ERN1 (0.55) | ALDH1A1KDM4ERAB9ASMN1; SMN2HPGD | |
| SCHEMBL18304652 | 0.82 | KAT6A (0.61) | ALDH1A1KDM4ERAB9ASMN1; SMN2HPGD | |
| SCHEMBL18311307 | 0.81 | KAT6A (0.57) | ALDH1A1KDM4ERAB9ASMN1; SMN2HPGD | |
| SCHEMBL27773463 | 0.80 | CHRNB1 (0.51) | ALDH1A1KDM4ERAB9ASMN1; SMN2HPGD | |
| SCHEMBL19662062 | 0.79 | TAAR1 (0.58) | ALDH1A1KDM4ERAB9AHPGDNPC1 | |
| SCHEMBL2389780 | 0.79 | ERN1 (0.57) | ALDH1A1KDM4ERAB9ASMN1; SMN2HPGD | |
| SCHEMBL2388588 | 0.79 | MAPT (0.64) | ALDH1A1KDM4ESMN1; SMN2HPGDCYP3A4 | |
| SCHEMBL2389984 | 0.77 | ERN1 (0.56) | ALDH1A1KDM4ERAB9ASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105209449-B | Inhibitors of the kynurenine pathway | 库拉德夫制药私人有限公司 | 2019-02-01 | — | — | CN | claimed |
| EP-2544679-B1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORP (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-2544679-B1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORP (US) | 2019-05-15 | — | — | EP | disclosed |
| CN-104710385-B | PDE10 inhibitor and compositions related and method | 奥默罗斯公司 | 2018-11-09 | — | — | CN | disclosed |
| US-10106516-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2018-10-23 | — | — | US | disclosed |
| CN-103402516-B | Compound, composition and application method as antiviral drugs | 富津世生物技术有限公司 | 2018-01-30 | — | — | CN | disclosed |
| CN-107445919-A | PDE10 inhibitor and compositions related and method | 奥默罗斯公司 | 2017-12-08 | — | — | CN | disclosed |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2017-06-01 | — | — | US | disclosed |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2017-06-01 | — | — | US | disclosed |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2017-06-01 | — | — | US | disclosed |
| EP-2544679-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | Omeros Corporation (US) | 2013-01-16 | — | — | EP | disclosed |
| CN-102869355-A | Pde10 inhibitors and related compositions and methods | OMEROS CORP | 2013-01-09 | — | — | CN | disclosed |
| US-8343970-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343970-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343970-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2011112828-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011112828-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106516-B2 | PDE10 inhibitors and related compositions and methods | PDE10A, PDE9A, PDE7A | ALDH1A1 2053/4885KDM4E 2629/4885RAB9A 89/4885 |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | ALDH1A1 2053/4885KDM4E 2629/4885RAB9A 89/4885 |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | ALDH1A1 2053/4885KDM4E 2629/4885RAB9A 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.